Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31510972 | 0.93 | TRPV4 (0.41) | TRPV4KDM4EUSP2ALDH1A1HTR2A | |
| SCHEMBL14720180 | 0.85 | ALDH1A1 (0.44) | KDM4EUSP2ALDH1A1HTR2ACYP11B1 | |
| SCHEMBL30266491 | 0.84 | TRPV4 (0.47) | TRPV4KDM4EUSP2ALDH1A1HTR2A | |
| SCHEMBL10537256 | 0.84 | TRPV4 (0.47) | TRPV4KDM4EUSP2ALDH1A1HTR2A | |
| SCHEMBL11963120 | 0.82 | TRPV4 (0.50) | TRPV4KDM4EUSP2ALDH1A1HTR2A | |
| SCHEMBL16122074 | 0.82 | KDM4E (0.48) | TRPV4KDM4EUSP2ALDH1A1HTR2A | |
| SCHEMBL28691142 | 0.82 | XDH (0.38) | TRPV4KDM4EALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL29447083 | 0.82 | XDH (0.38) | TRPV4KDM4EALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL4001974 | 0.81 | CYP11B1 (0.42) | TRPV4HTR2AHTR2CCYP11B1CYP11B2 | |
| SCHEMBL31753998 | 0.80 | AR (0.41) | TRPV4ALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
| CN-115698001-A | N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2632464-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | TRPV4 384/4885KDM4E 1908/4885USP2 4693/4885 |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | TRPV4 4830/4885KDM4E 974/4885USP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.